by Raymond Tel | Aug 1, 2022 | News
We at Sulfateq are very proud to have reached the finals out of more than twenty applications. The Innovation Award is awarded to the innovation with the most impact in the field of Life Sciences & Health. During the final on September 27, we will pitch our...
by Miquel Estevez | Mar 4, 2022 | News
Winter sleep (hibernation) offers hibernating species the possibility to survive harsh environmental conditions, such as periods of low food availability or periods of extreme low temperatures. Hibernators lower their body temperature, breathing- and heart rate and...
by Vincent Schermer | Aug 24, 2021 | News
Groningen, The Netherlands & Ankara, Turkey – Sulfateq BV, an early stage biotech company developing a group of small molecules that maintain mitochondrial health, and GEN İlaç ve Sağlık Ürünleri Sanayi ve Ticaret A.Ş. (GEN), a publicly traded company...
by Daniel | May 18, 2021 | News
Sulfateq is happy to announce that a new scientific manuscript detailing the efficacy of SUL-151 to mitigate the development of Chronic Obstructive Pulmonary Disease (COPD), was recently published in the International Journal of Molecular Sciences. This manuscript...
by Raymond Tel | Dec 14, 2020 | News
Groningen, The Netherlands & Ankara, Turkey – Sulfateq BV, an early stage biotech company developing a group of small molecules that maintain mitochondrial health, and GEN İlaç ve Sağlık Ürünleri Sanayi ve Ticaret A.Ş. (GEN), a leading speciality...
by Raymond Tel | Feb 25, 2020 | News
We are proud to announce that Sulfateq B.V. received a Samenwerkingsverband Noord-Nederland (SNN) Valorisation grant for the development of SUL-138 as Acute Kidney Injury (AKI) prophylaxis. This grant helps us to continue the development that was already stimulated by...
